2nd quarter and first half 2019 report

15. Aug 2019 | 3 min read

 

Moss 15.08.19


Gentian Diagnostics AS announces its results for the second quarter and first half of 2019.
The highlights include:
 
  • 16 % growth in sales revenue in 2Q19 compared to 2Q18
  • Total sales revenues of MNOK 10.2 in 2Q19, up from MNOK 8.8 in 2Q18
  • FDA 510(k) clearance for the BÜHLMANN fCAL® turbo and with this access to the US market
  • In July, Beckman Coulter, one of the top 5 global diagnostics companies, and Gentian have prolongated the trusted partnership agreement by another 6 years
  • In August, Gentian announced the sales channel agreement for fCAL® turbo between Roche Diagnostics and Gentian’s sales partner Bühlmann Laboratories AG

 

Please find the report and results presentation enclosed:

GDAS 2019 1H interim report

GDAS 2019 1H interim presentation

 

For further information, please contact:

Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

 

MeldingsID: 482926

 

You may also read


Dec 16, 2019 - Kristin Hart

Financial calendar

Financial calendar for Gentian Diagnostics AS

Dec 05, 2019 - Kristin Hart

Gentian Diagnostics presents at DNB conference in New York

Moss 05.12.19 The CEO of Gentian Diagnostics, Dr. Hilja Ibert, will today give a company presentation at the..

Nov 29, 2019 - Kristin Hart

Share capital increase registered

Reference is made to the stock exchange notice from Gentian Diagnostics AS (the "Company") on 25 November..